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ALK inhibition activates 
LC3B‑independent, protective 
autophagy in EML4‑ALK positive 
lung cancer cells
Anna M. Schläfli1*, Igor Tokarchuk1,2, Sarah Parejo1, Susanne Jutzi1, Sabina Berezowska1,3, 
Nikolai Engedal4,5,6 & Mario P. Tschan1,2,6
ALK inhibitors effectively target EML4‑ALK positive non‑small cell lung cancer, but their effects are 
hampered by treatment resistance. In the present study, we asked whether ALK inhibition affects 
autophagy, and whether this may influence treatment response. Whereas the impact of targeted 
therapies on autophagic activity previously have been assessed by surrogate marker proteins 
such as LC3B, we here thoroughly examined effects on functional autophagic activity, i.e. on the 
sequestration and degradation of autophagic cargo, in addition to autophagic markers. Interestingly, 
the ALK inhibitor Ceritinib decreased mTOR activity and increased GFP‑WIPI1 dot formation in H3122 
and H2228 EML4‑ALK+ lung cancer cells, suggesting autophagy activation. Moreover, an mCherry‑
EGFP‑LC3B based assay indicated elevated LC3B carrier flux upon ALK inhibition. In accordance, 
autophagic cargo sequestration and long‑lived protein degradation significantly increased upon ALK 
inhibition. Intriguingly, autophagic cargo flux was dependent on VPS34 and ULK1, but not LC3B. 
Co‑treating H3122 cells with Ceritinib and a VPS34 inhibitor or Bafilomycin A1 resulted in reduced 
cell numbers. Moreover, VPS34 inhibition reduced clonogenic recovery of Ceritinib‑treated cells. In 
summary, our results indicate that ALK inhibition triggers LC3B‑independent macroautophagic flux in 
EML4‑ALK+ cells to support cancer cell survival and clonogenic growth.
Lung cancer accounts for the largest number of cancer deaths worldwide. It can be divided into small cell and 
non-small cell lung cancer (NSCLC)1. Several driver mutations and oncogenic gene fusions have been identi-
fied, such as EGFR, c-MET, ROS1 and KRAS  mutations2, and rearrangements of ALK, RET, and  ROS13, which 
are in the era of precision medicine inhibited by targeted therapies. In the present study, we focused on lung 
cancers harboring the EML4-ALK fusion protein, found in 2–9% of all NSCLC patients. The ALK gene encodes 
a transmembrane tyrosine kinase  protein4, and the EML4 gene belongs to a large family of proteins, which are 
associated to  microtubules5. Different variants of the EML4-ALK gene have been identified, all containing the 
entire kinase domain of ALK and minimally the N-terminal coiled-coil region of EML4, required for constitu-
tive self-activation of  ALK6. Downstream of EML4-ALK the PI3K/AKT, JAK/STAT and the MAPK pathway are 
 activated6.
In the clinic, ALK fusions are targeted by tyrosine kinase inhibitors. The first generation ALK inhibitor is 
Crizotinib, which also blocks c-Met7. Although primary response rates are promising, resistance to treatment 
occurs  rapidly4. In the present study, we used the  2nd generation ALK inhibitor Ceritinib. Ceritinib is more potent 
than Crizotinib in both in vitro enzymatic assays and in xenograft experiments in  mice8. Furthermore, Ceritinib 
is active against some of the common Crizotinib-resistant ALK  mutations8. In patients, Ceritinib treatment has 
been shown to prolong progression-free survival compared to  Crizotinib4. Although Ceritinib is a preferred 
alternative to Crizotinib, almost all patients develop resistance also to  Ceritinib4. Another  2nd generation ALK 
inhibitor, Alectinib, has been approved for first-line treatment of advanced ALK-positive NSCLC due to its 
superior activity in the CNS and that it may overcome resistance to Crizotinib. However, acquired resistance to 
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Alectinib occurs, and remains problematic. As for Crizotinib and Ceritinib, resistance to Alectinib commonly 
develops due to ALK mutations, as it was observed in 53% of the tumors from a large cohort of two pooled clinical 
 trials9. In the other ~ half of the patients, the resistance mechanisms were not clear. No randomised trials have 
compared Alectinib with the other  2nd- or  3rd-generation ALK TKIs. The  3rd generation ALK-inhibitor Lorlatinib 
is promising for overcoming progression on  2nd generation inhibitors Ceritinib and Alectinib, but not all patients 
 respond10. Chemotherapy is still the backbone of NSCLC, including in ALK-positive patients progressing after 
ALK TKIs without actionable resistance mutations. This clearly warrants evaluation of alternative means to 
overcome resistance to ALK-inhibition. A cellular process, which may support drug resistance, is  autophagy11, 12. 
Autophagy is a cellular degradation and recycling pathway active at basal levels in all cells. Macroautophagy 
(referred to as autophagy from here on) is the type of autophagy that has been best studied and involves the 
production of double-membrane vesicles, termed autophagosomes. These specialized vesicles are dedicated to 
transport cytoplasmic cargos, such as proteins or damaged organelles to lysosomes, where autophagosomes fuse 
with lysosomes and are degraded together with their  load13.
Experimental evidence generally supports the notion that autophagy suppresses oncogenic transformation 
by preserving cellular homeostasis and genomic  fidelity14, 15. However, in advanced tumors, high autophagic 
activity may in some cases be proficient for the cancer cells as it can support survival under adverse conditions 
such as low nutrient and oxygen  supply14, 15. Cancer therapy adds another complexity, as anti-cancer agents 
frequently modulate autophagy. Many cancer drugs appear to induce autophagy, that in turn protects the  cells12. 
This prompted many researches to combine cancer therapies with autophagy inhibitors to improve therapeutic 
 efficiency16–19. On the other hand, autophagy may in some instances be non-protective20, or even contribute 
to drug-induced cell  death21. Thus, the role of autophagy in cancer cell drug-response seems to be context-
dependent. Importantly, however, previous studies on the effects of chemotherapeutic drugs on autophagy are 
predominantly or exclusively based on analyses of autophagic markers (predominantly LC3) rather than on 
functional autophagic activity (i.e. the sequestration and degradation of autophagic cargo). Moreover, the role 
of autophagy has typically been elucidated by interference with autophagy-related (ATG) genes, most of which 
have non-autophagic roles that may affect cell  viability22, 23. Thus, the effect of anti-cancer drugs on autophagic 
activity in cancer cells and its role in treatment responses still remains largely unclear, and requires careful study.
In the present study we aimed at first elucidating if Ceritinib influences autophagy in EML4-ALK positive 
NSCLC cells, and second whether its modulation affects treatment response to ALK inhibition. We used several 
methods to determine autophagy and, importantly, autophagic flux, including long-lived protein degradation 
assay (LLPDA) and lactate dehydrogenase (LDH) sequestration assay. We further assessed the effects of VPS34-
inhibition as well as ULK1- and LC3B-knockdown on autophagy. Based on the results from all these assays we 
conclude that Ceritinib triggers VPS34- and ULK1-dependent autophagy. Interestingly, however, LC3B appeared 
to be dispensable for Ceritinib-induced autophagy. Lastly, we found that blocking autophagy by VPS34 inhibi-
tion significantly decreased cell numbers and clonogenic growth when combined with Ceritinib. In summary 
our results indicate that Ceritinib induces LC3B-independent, cytoprotective autophagy in EML4-ALK positive 
NSCLC cells.
Results
Ceritinib decreases cell viability and activates autophagy in EML4‑ALK positive NSCLC 
cells. We first aimed at determining the sensitivity of EML4-ALK positive H3122 and H2228 NSCLC cells to 
ALK inhibition. To this end, we treated the cells with different concentrations of Crizotinib or Ceritinib and per-
formed Alamarblue viability assays. Treatment with increasing concentrations of both drugs for 3 days resulted 
in a gradual decrease in cell viability (Fig. 1A). In agreement with previous  data18 we found H3122 (Fig. 1A, 
left panel) to be more sensitive to ALK inhibition than H2228 cells (Fig. 1A, right panel) and Ceritinib to be 
more potent than Crizotinib. Our data indicated approximate IC50 values of 1 µM and 10 µM Crizotinib, and 
100 nM and 5 µM Ceritinib in H3122 and H2228 cells, respectively (Fig. 1A). H3122 and H2228 cells showed 
similar sensitivity to growth inhibition upon treatment with another  2nd generation ALKi, Alectinib, whereas 
H3122 cells were more sensitive than H2228 cells to the  3rd generation ALKi Lorlatinib (Supplementary Fig. 1A). 
EML4-ALK negative A549 NSCLC cells showed significant resistance to all ALK-inhibitors tested (Supplemen-
Figure 1.  Ceritinib decreases cell viability, abolishes ALK phosphorylation and activates autophagy in EML4-
ALK positive NSCLC cells (A) H3122 and H2228 cells were treated with Crizotinib or Ceritinib with indicated 
concentrations for 3 days before metabolic activity was determined using Alamarblue assay (n = 2). Two-Way 
ANOVA was applied to compare the two drugs. ****p < 0.0001, **p < 0.01. (B) Western Blot for p-mTOR, 
p-ULK1, p-EML4-ALK and p-p70S6K is shown of protein lysate from H3122 and H2228 cells treated with 
0, 0.1 or 1 µM Ceritinib for 24 h. Total protein serves as a loading control. (C) Confocal microscopy pictures 
of GFP-WIPI1 transiently over-expressed in H3122 cells treated with DMSO (Ctrl) or Ceritinib for 18 h. 
(D) Quantification of GFP-WIPI1 dots shown in C. Dot plot includes data from 3 independent experiments 
with 6–7 pictures per experiment (n = 20/21). Mann–Whitney U, **p < 0.01. (E) Histograms representing 
the mCherry to GFP ratio of H3122 and H2228 cells stably expressing the mCherry-EGFP-LC3B construct 
after Ceritinib treatment (0–1 µM for 24 and 48 h, n = 3). (F) Quantification of the ratiometric FACS analysis 
performed in H. Kruskal–Wallis followed by Dunn`s multiple comparison was applied for statistical testing 
*p < 0.05, **p < 0.01, ***p < 0.001. (G) p62 dots were analyzed by immunofluorescence after H3122 cells were 
treated with Ceritinib (18 h) ± BafA (last 2 h). Nuclei were counterstained with DAPI. (H) Left panel: Bar plot 
shows quantification of p62 dots shown in G. Experiment has been performed 3 times. Right panel: p62 flux 
calculated based on the p62 dot quantification by subtracting the BafA untreated sample from its respective 
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tary Fig. 1A). Phosphorylation of EML4-ALK at Tyrosine 1604 (p-EML4-ALKTyr1604) was virtually undetectable 
after 24 h of treatment with 100 nM Ceritinib, Alectinib or Lorlatinib in both H3122 and H2228 cells (Fig. 1B, 
Supplementary Fig. 1B–D), indicating an efficient and long-term inhibition of ALK. Of note, however, some 
residual level of p-EML4-ALKTyr1604 could be observed in Ceritinib-treated H2228 cells (Fig. 1B). ALK has been 
shown to signal via the PI3K/AKT/mTOR pathway in different cell  lines24. In line with this, Ceritinib induced a 
slight decrease in mTOR phosphorylation at Serine 2448 and concomitantly a strong reduction in phosphoryla-
tion of the downstream mTOR target p70S6 Kinase at Threonine 389 (p-p70S6KThr389) in both cell lines (Fig. 1B, 
Supplementary Fig. 1B). The levels of the inhibitory phosphorylation of ULK1 at Serine 757 (p-ULK1S757, elicited 
by mTOR) also decreased in Ceritinib-stimulated conditions in H3122 cells (Fig. 1B). Importantly, Ceritinib 
treatment did not change phosphorylation of mTOR, p70S6 and ULK1 in EML4-ALK negative A549 cells (Sup-
plementary Fig. 1B). Inhibiting EML4-ALK using Alectinib or Lorlatinib resulted in a similar mTOR, p70S6 
and ULK1 phosphorylation pattern as seen with Ceritinib treatment (Supplementary Fig. 1C–D).These results 
suggest that ALK inhibition reduces mTOR activity in H3122 EML4-ALK+ NSCLC cells, and that this leads 
to activation of ULK1 (via removal of the inhibitory phosphate group at Serine 757), which in turn may lead 
to initiation of macroautophagy. We therefore assessed autophagy activation through analysis of WIPI1 dot 
formation. WIPI1 is an early autophagy marker, and an increase in WIPI1 dots is associated with autophagy 
 activation25. To this end, we transiently over-expressed GFP-WIPI1 in H3122 cells and treated the cells with 
DMSO or Ceritinib. We found a significantly increased number of WIPI1-positive dots upon ALK inhibition 
with 1 µM Ceritinib for 18 h (Fig. 1C–D), suggesting autophagy activation. In order to corroborate our data, 
we further determined autophagy by assessing LC3B carrier flux. LC3B is one of the most commonly used 
markers to measure autophagy. It is present at autophagic vesicles very early on and stays attached even when 
the autophagosome reaches the lysosome. To monitor the flux of LC3B to autolysosomal (acidic) vacuoles, tan-
dem fluorescent LC3B constructs such as mCherry-EGFP-LC3B have been  developed26. Upon arrival to acidic 
environments (amphisomes and autolysosomes) the EGFP fluorescence is quenched (and degraded), whereas 
mCherry is more  resistant26. Using the mCherry-EGFP-LC3B construct, we found a dose- and time-dependent 
increase in LC3B carrier flux upon Ceritinib treatment in H3122 and H2228 cells (Fig. 1E–F). In agreement with 
the lower sensitivity of H2228 cells to Ceritinib (Fig. 1A) and the indications of residual p-EML4-ALKTyr1604 lev-
els and mTOR activity in this cell line (Fig. 1B), LC3B carrier flux was less pronounced upon ALK inhibition in 
H2228 compared to H3122 cells (Fig. 1E–F). Next, we evaluated p62 levels upon ALK inhibition in H3122 cells. 
p62 is an autophagy receptor that helps in recruiting specific cargo, such as ubiquitinated protein aggregates, to 
 autophagosomes27. Upon Ceritinib treatment, p62 dots (visualized by indirect immunofluorescence) increased 
from about three dots/cell to eight dots/cell (Fig. 1G–H). Importantly, lysosomal blockage using BafA drastically 
increased the number of endogenous p62 dots/cell, particularly in Ceritinib-treated cells (Fig. 1G–H). Calcu-
lating the p62 flux revealed a fivefold higher lysosomal p62 turnover under Ceritinib treatment compared to 
control conditions (Fig. 1H, right panel).
In summary, our data indicate that Ceritinib is a potent ALK inhibitor, which activates ULK1 kinase via 
mTOR inhibition. Furthermore, Ceritinib increases autophagy initiation and carrier flux in NSCLC cells, which 
in light of the involvement of p62 may include selective autophagy.
Ceritinib triggers ULK1‑ and VPS34‑dependent autophagy. LC3B, p62 and WIPI1 are part of the 
autophagic machinery, but do not represent autophagic cargo. Moreover, they may be involved in processes 
other than autophagy. Therefore, these markers alone cannot provide accurate information about autophagic 
cargo flux.
Therefore, we next examined autophagy by looking into its function, namely the degradation of proteins. In 
order to do so, we performed a  LLPDA28 to compare proteolysis in the lysosomal compartment under basal con-
ditions versus Ceritinib treatment. Ceritinib triggered a significant increase in protein degradation in H3122 cells 
(Fig. 2A). Importantly, BafA, which blocks lysosome  acidification29, 30 and thereby function, virtually abolished 
Ceritinib-induced proteolysis (Fig. 2A). Since lysosome inhibition also affects chaperone-mediated autophagy, we 
repeated the LLPD assay in H3122 cells using macroautophagy-specific inhibitors, namely SAR-405 or VPS34-
IN1, which both target VPS34. Using that experimental set-up, we found that Ceritinib increases both lyso-
some- and VPS34-sensitive proteolysis, strongly indicating that Ceritinib increases macroautophagic cargo flux 
(Fig. 2B and Supplementary Fig. 2A–C). In order to substantiate our data, we next assessed autophagy using the 
LDH sequestration assay. LDH is a cytosolic macroautophagy cargo, and its sequestration by autophagosomes 
serves as a specific measure of autophagic  flux31. Autolysosomal inhibitors, like BafA, block LDH degradation, 
and performing the experimental treatment in the absence or presence of BafA thus allows specific assessment 
of treatment effects on autophagic  sequestration31. In line with the LLPDA data, Ceritinib, as well as Alec-
tinib and Lorlatinib, significantly increased LDH sequestration in the presence of BafA, but not in its absence 
(Fig. 2C–D), indicating that ALK inhibition increases autophagic sequestration activity (autophagosome forma-
tion). To strengthen this conclusion, we performed the LDH sequestration assay in the presence or absence of 
pharmacologic inhibition of macroautophagy using SAR-405 (VPS34 inhibitor). Strikingly, VPS34 inhibition 
virtually completely abolished Ceritinib-induced LDH sequestration (Fig. 2C), indicating that Ceritinib induces 
VPS34-dependent autophagy. Next, we used the ULK1/2 inhibitor MRT68921 to validate the VPS34 inhibition 
data. Similar to VPS34 inhibition, treatment with MRT68921 significantly reduced Ceritinib- as well as Alectinib- 
and Lorlatinib-induced LDH sequestration (Fig. 2D, left panel). Importantly, control experiments with EML4-
ALK-negative A549 cells revealed reduced or no increase in cargo sequestration upon ALK inhibition (Fig. 2D, 
right panel). Next, we knocked down ULK1 to validate the findings from pharmacologic ULK inhibition. Two 
H3122 ULK1 knockdown cell lines harboring each a different shRNA to target ULK1 showed strongly reduced 
LDH sequestration in response to Ceritinib treatment compared to control-transduced cells (Fig. 2E) (albeit 
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Figure 2.  Ceritinib triggers ULK1- and VPS34-dependent autophagy (A) Bar plot represents percent 
proteolysis of H3122 cells after treatment with DMSO or Ceritinib for 24 h in the presence or absence of BafA 
during the last 5 h (n = 3). (B) Quantification of BafA-sensitive and SAR-405-sensitive proteolysis in H3122 
cells after treatment with 1 µM Ceritinib for 24 h (n = 3). Percent proteolysis was determined and calculated as 
described in the methods section. (C) H3122 cells were treated with DMSO or 1 µM Ceritinib (24 h) ± BafA 
and ± SAR405 (during the last 3 h) before LDH sequestration was determined (n = 3). (D) H3122 and A549 cells 
were treated with DMSO or 1 µM Ceritinib/Alectinib/Lorlatinib (24 h) ± BafA and ± MRT68921 (during the 
last 3 h) before LDH sequestration was determined (n = 3). (E) H3122 control (shCtrl) and two ULK1 knock 
down (shULK1#1 and shULK1#2) cell lines were subjected to LDH sequestration assay after 18 h of Ceritinib 
treatment. BafA was added during the last 3 h (n = 3). (F) Experiment as in E, but with H3122 shCtrl, shLC3B#1 
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the effect of the first shRNA did not reach p < 0.05 statistical significance). Knockdown efficiency for ULK1 was 
around 80% (Supplementary Fig. 2D). In contrast to ULK1 silencing, knockdown of LC3B failed to significantly 
reduce Ceritinib-induced LDH sequestration (Fig. 2F), in spite of very efficient depletion (80% and 90% reduc-
tion of LC3B-II protein levels with shRNA #1 and #2 respectively (Supplementary Fig. 2E).
Collectively, these data indicate that ALK inhibition induces a canonical form of autophagy (dependent on 
VPS34 and ULK1) in EML4-ALK positive NSCLC cells, which, however, is independent of LC3B.
Blocking autophagy via VPS34 inhibition enhances Ceritinib‑induced reduction in cell viability 
and clonogenic growth. Having established that ALKi triggers autophagy in EML4-ALK+ NSCLC cells, 
we asked whether its inhibition could increase ALKi-based treatment efficiency. To this end, we challenged 
the cells with Ceritinib in the presence or absence of the VPS34 inhibitor VPS34-IN1, and determined living 
cell numbers after 2 days of treatment. The numbers of living cells at day 2 were reduced with the combina-
tion as compared to treatment with Ceritinib or VPS34-IN1 alone (Fig. 3A), suggesting that Ceritinib-induced 
autophagy plays a cytoprotective role in NSCLC cells. Importantly, the combination treatment also significantly 
reduced the ability of the remaining living cells to form colonies after drug removal (Fig. 3B–C). As a proof of 
principle, we used BafA to block autophagy at a late stage and repeated the experiment. BafA did indeed mimic 
VPS34-IN1 in reducing the number of living cells when combined with Ceritinib for 2 days (Fig. 3D), thus 
supporting the notion that Ceritinib induces protective autophagy in NSCLC cells. Surprisingly, however, the 
remaining living cells were very potent in recovery from treatment, as shown by the clonogenic assay (Fig. 3E–
F). Finally, we used a more clinically relevant late stage autophagy inhibitor, chloroquine (CQ) in combination 
with Ceritinib. CQ treatment did not significantly reduce H3122 cell viability or clonogenic recovery, either in 
the absence of presence of Ceritinib (Fig. 3G–I). Together, inhibiting autophagy at an earlier stage with a VPS34 
inhibitor clearly enhanced Ceritinib-induced toxicity.
Discussion
A large number of studies reported that autophagy is induced upon cancer therapy. In this regard, our data 
are in line with previous findings, including several studies using pharmacological ALK inhibition in different 
cancer  types32–35. In all these studies the authors found an increase in autophagy-associated markers, mainly 
 LC3B32–35, but the sequestration and degradation of autophagic cargo has not been assessed. Moreover, Toros-
sian A. et al. reported that treating ALK-positive anaplastic large cell lymphoma (ALCL) cells with Crizotinib 
caused a downregulation of BCL-2 paralleled by increased autophagy. Importantly and different to our study 
with EML4-ALK positive NSCLC cells, combining Crizotinib with autophagy inhibition to treat ALCL cells 
did not result in increased cell death, indicating autophagy-associated cell  death36. Therefore, the type of ALK 
rearrangement as well as the degree of autophagy activation upon ALK inhibition can determine the type of 
autophagy modulation required to improve current ALK inhibitor therapies.
Our study is unique in that it thoroughly and conclusively demonstrates that a targeted therapy can enhance 
full autophagic cargo flux in cancer cells. Moreover, our study is the first to measure autophagy upon Ceritinib-
mediated inhibition of EML4-ALK in NSCLC cells. Of note, we also found induction of autophagy, although to a 
clearly lesser degree, in EML4-ALK negative A549 lung cancer cells treated with Ceritinib but not with Alectinib 
or Lorlatinib (Fig. 2D). This might be explained by the fact that this drug can also inhibit insulin-like growth 
factor type 1 receptor (IGF-1R) signalling and thereby attenuate A549 cell  growth37, 38.
Interestingly, there is a growing list of reports that describe LC3B-independent  autophagy39–43. To the best of 
our knowledge, our study is the first to report that a therapeutic anti-cancer drug can induce LC3B-independent 
autophagy. The ATG8 family, to which LC3B belongs, contains six more members, namely LC3A, LC3B2, LC3C, 
GABARAP, GABARAPL1 and  GABARAPL244. There is a certain degree of specialization among ATG8 family 
 members44 but they may also partially compensate each other, and the lack of one member might not be sufficient 
to block or slow down autophagic flux. In light of this, we would like to emphasize, as it has been done by other 
 groups40, 45, that we should not draw conclusions from LC3B-based autophagy assays only.
Rather surprisingly, we found increased autophagic activity using a fluoresecent tagged LC3B assay although 
Ceritinib-induced autophagy did not require LC3B. We speculate that the autophagosomes that mediate Ceri-
tinib-induced autophagy are LC3B positive and thus the autophagic flux can be measured with an exogenously 
provided tandem Cherry-EGFP-LC3B construct. LC3B thus seems to be a redundant passenger in Ceritinib-
induced autophagy. Most likely, other ATG8 proteins such as the GABARAPs are required instead of LC3B. 
Similar results have been found in LNCaP cells treated with the ER stressor tunicamycin. Tunicamycin induced 
LC3B flux as assessed by a tandem fluorescence assay, yet knockdown of LC3B did not reduce autophagic cargo 
 flux41. Furthermore, it is possible that LC3B-independent induction of autophagic cargo flux by Ceritinib is 
cell-line specific. However, LC3B-independent autophagy has been reported in several different cell lines/types, 
including primary  hepatocytes39, LNCaP  cells39, 41 and HeLa  cells42, 43. In all these cases, autophagy induction 
was dependent on GABARAP rather than LC3 proteins.
Although, we cannot exclude non-specific drug effects, we believe that the different impact of VPS34-IN1 
versus BafA on the colony-formation ability of Ceritinib-treated cells may be related to the fact that VPS34-IN1 
inhibits autophagy at an early  stage46, whereas BafA affects autophagy at a later stage. BafA neutralizes lyso-
some acidity and thereby  function29, 30, and eventually reduces the fusion of lysosomes with  autophagosomes29. 
2-days treatment with BafA and Ceritinib will therefore, unlike VPS34-IN1 and Ceritinib, induce a massive 
accumulation of autophagosomes and inactive autolysosomes in the cells. When the cells are released from 
the BafA-mediated block upon initiating the clonogenic assay (the drugs are washed out before re-plating), the 
halted autophagosomes and autolysosomes will be re-activated, and the sequestered cytoplasmic content will be 
degraded. The extra energy and cellular building blocks that are thus released to the cytosol may very well boost 
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Figure 3.  Blocking autophagy via VPS34 inhibition sensitizes cells to Ceritinib (A) H3122 cells were treated 
with DMSO or 1 µM Ceritinib in the presence or absence of VPS34-IN1 for 2 days before living cells were 
counted and re-seeded for clonogenic assays. Bar plot represents percent of living cells compared to control 
treated cells (n = 4). (B) Clonogenic assay of experiments as described in A. After 2 days of treatment, 5 ×  103 
living cells were re-seeded and kept for 10 days without treatment. Thereafter, colonies were stained with crystal 
violet and counted. (C) Quantification of the clonogenic assays described in A (n = 4). (D) H3122 cells were 
treated with DMSO or 1 µM Ceritinib in the presence or absence of increasing concentrations of BafA (40, 80 
and 120 nM) for 2 days before living cells were counted and quantified from 5 independent experiments as in A. 
(E) Clonogenic assay of cells as described in D. Living cells were re-seeded at low density (5 ×  103 cells per well 
in a 6-well plate) and cultured in the absence of drugs for 10 days. Colonies were counterstained using crystal 
violet and counted. (F) Quantification of colonies shown in E (n = 5). (G) H3122 cells were treated with DMSO 
or 1 µM Ceritinib in the presence or absence of 15 µM chloroquine and asssessed as in A (n = 3). (H) Clonogenic 
assay of chloroquine (CQ) treated cells as described in G and assessed as in B. (I) Quantification of colonies 
shown in H (n = 3).
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the clonogenic recovery of the cells that had been treated with BafA and Ceritinib. Indeed, this could explain 
the tendency of BafA to even increase colony formation in Ceritinib-treated cells (Fig. 3F). CQ, on the other 
hand, was shown to cause a series of cellular alterations in addition to prevent autophagosome-lysosome fusion, 
possibly explaining its inhibitory activity in colony formation assays compared to  BafA30.
In terms of improving long-term therapeutic effects of anti-cancer drugs like Ceritinib, VPS34 inhibiton or 
early-stage autophagy inhibition in general may thus be better suited than blocking autophagy at later stages. In 
future studies, it will be interesting to explore whether this holds true in general and if applying VPS34 inhibi-
tion to the many anti-cancer drugs that have been shown to induce cytoprotective autophagy in various types of 
cancer cells could improve treatment  efficacy47, 48. If this is the case, it may help explain the limited clinical success 
of using the late-stage inhibitor hydroxychloroquine (the only clinically approved autophagy inhibitor so far) 
in combination with chemotherapy, and point towards novel early-stage autophagy inhibitors, like VPS34-IN1 
and others, to hold greater promise for combination therapy with anti-cancer drugs.
Methods
Cell lines and culture conditions. H3122 and H2228 cells were obtained from the American Type Cul-
ture Collection (ATCC) and were cultured in RPMI-1640 (Sigma-Aldrich, R8785). A549 cells were provided by 
PD Dr. phil. nat. Thomas M. Marti (Department for BioMedical Research (DBMR), University of Bern, Bern 
Switzerland) and maintained in Dulbecco’s modified Eagle’s medium/ F-12 Ham (DMEM-F12) (Sigma-Aldrich, 
D8437). All three cell lines were supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, F7524), 50 
U/mL penicillin and 50 µg/mL streptomycin (Sigma-Aldrich, P4333). Futhermore, all cell lines were kept at 
37 °C with 5%  CO2 humidified air and were split 3 times a week using Trypsin–EDTA 0.25% (Sigma-Aldrich, 
T4049) to detach cells. 293T cells were used for lentivirus production and cultured in DMEM (Sigma-Aldrich, 
D6046) supplemented with 5% FBS, 1% penicillin/streptomycin, and 1% HEPES (Sigma-Aldrich, H3375) in a 
humidified incubator with 7.5%  CO2 at 37 °C.
Lentiviral vectors. pLKO.1-puro lentiviral vectors expressing shRNA targeting LC3B 
(shLC3B#1 = NM_022818.2-292s1c1, shLC3B#2 = NM_022818.2-247s1c1) or ULK1 (shULK1#1 = NM_003565.x-
535s1c1, shULK1#2 = NM_003565.x-1772s1c1) were purchased from Sigma-Aldrich. Lentivirus production was 
performed in 293T  cells using a 3rd generation packing system described  in49. The packaging plasmids and 
the vectors encoding the shRNA of interest were added to 293T cells using the calcium precipitation method. 
293T cells were incubated at 5%  CO2 for 16 h before media was changed. Cells were put back to 7.5%  CO2 and 
48 h later the viral particle-containing supernatants were harvested and passed through a 0.45 µm filter. H3122 
cells were infected twice with filtered supernatant. Transduced cells were selected with 1.5 µg/ml puromycin for 
3 days, before lowering the concentration to 0.5 μg/ml for another 4 days. After recovery, knockdown efficiency 
was assessed by western blot analysis and assays of interest were performed.
Chemicals. Crizotinib (PF-02341066, Selleckchem, S1068), Ceritinib (LDK378, Selleckchem, S7083) and 
Lorlatinib (PF-6463922, Selleckchem, S7536) were dissolved in DMSO at a stock concentration of 10 mM. Alec-
tinib (CH5424802, Selleckchem, S2762) was dissolved in DMSO at a concentration of 2 mM. The above men-
tioned chemicals were stored at -80  °C. Bafilomycin A1 (Enzo-Life sciences, BML-CM110) was dissolved in 
DMSO at a stock concentration of 200 µM. Chloroquine (Sigma-Aldrich, C6628) was reconstituted in distilled 
water to 10 mM. Both inhibitors were stored at − 20 °C. For autophagic flux measurements, Bafilomycin A1 was 
used at a final concentration of 200 nM and added during the last 2–5 h of treatment depending on the method 
used. For the clonogenic assay, chloroquine was added at a concentration of 15 µM and incubated for 48 hr 
prior to re-seeding. The ULK1 Inhibitor MRT68921 (Sigma-Aldrich, SML1644) was dissolved in water at a final 
concentration of 20 mM and stored at -80 °C. SAR-405 from ApexBio (A8883) and VPS34-IN1 (S7980) from 
Selleckchem were dissolved in DMSO to 50 mM and stored at -80 °C. For the LDH experiments, MRT68921 
was used at a concentration of 7.5 µM and VPS34-IN1 at 5 µM. Water served as vehicle control for MRT68921, 
whereas DMSO (Sigma-Aldrich, D4540) was used as a vehicle control for all other drugs dissolved in DMSO.
Western blotting. Protein lysates were prepared by extracting the total protein from cell pellets using urea 
lysis buffer (8 M Urea, 0.5% Triton X-100). After protein quantification using Bradford assay (BioRad, 5,000,006) 
15–20 µg protein were loaded on 4–20% Mini-PROTEAN TGX Precast Protein Gels (BioRad, 4,561,096) and 
transferred to PVDF membranes (Trans-Blot Turbo Mini PVDF Transfer Packs, BioRad 1,704,156) using the 
Trans Blot Turbo Transfer System.
(Bio-Rad Laboratories AG, Pra Rond 23,1785 Cressier). Thereafter, membranes were blocked in either 5% 
milk or 5% BSA for 1 h at RT while shaking. Subsequently, membranes were put into primary antibody solu-
tion: Anti-LC3B antibody (NB600-1384, Novus Biologicals) and p-p70S6K (9234, Cell Signaling) 1:1000 in 5% 
Milk 3 h RT and p-ALK (Cell Signaling 3341), p-ULK1 (Cell Signaling, 6888), ULK1 (Cell Signaling 4773S) 
and p-mTOR (Cell Signaling, 5536) 1:1000 in 5% BSA overnight at 4 °C. After washing with TBS-T and TBS, 
membranes were incubated with HRP-conjugated secondary goat anti-rabbit antibody (Cell signaling) diluted 
1:10 000 in 5% milk for 1–3 h at RT. Membranes were washed again and proteins detected using the Clarity 
Western ECL Substrate (BioRad, 1,705,061) and the ChemiDoc MP system (Bio-Rad Laboratories AG, Cressier) 
to detect the signal. Saturation of the signal was reported by the software in order to avoid over-exposure of the 
blots. Quantification of LC3B-II and LC3B carrier flux was performed as described  in44.
Microscopy of GFP‑WIPI1 dots. For over-expression of GFP-WIPI1, cells were seeded on 18 × 18 mm 
glass slides (Menzel-Gläser) inserted to 6-well plates (Sarstedt 83.3920.005) at a density of 0.3 ×  106 cells/well. 
9
Vol.:(0123456789)
Scientific Reports |         (2021) 11:9011  | https://doi.org/10.1038/s41598-021-87966-6
www.nature.com/scientificreports/
24 h post-seeding, media was changed and GFP-WIPI1 was delivered to cells using Lipofectamine2000 accord-
ing to the manufacturer’s instructions. We used 4  µg of DNA and 2  µl of Lipofectamine2000 per well. The 
DNA-Lipofectamine complexes were prepared in a total of 50 µl of Opti-MEM media (ThermoFisher Scientific, 
31,985,070). 16 h post-transfection, media was replaced by DMSO- or Ceritinib-containing media. 18 h after 
treatment, cells were washed, fixed with 4% PFA and mounted as described  in50. Confocal microscopy pictures 
were taken with a FluoView-1000 confocal microscope (Olympus Schweiz AG, Volketswil, Switzerland) with a 
63 × objective.
mCherry‑EGFP‑LC3B ratiometric FACS analysis. The procedure is described in detail  elsewhere50. 
Briefly, H2228 and H3122 cells were infected with a lentiviral construct harboring the mCherry-EGFP-LC3B 
construct. After Puromycin selection, cells were sorted for low to intermediate expression of mCherry fluores-
cence. For the experiment, 2 ×  105 cells were seeded in 6-well plates and were treated with different concentra-
tions of DMSO or Ceritinib the following day. 24 h and 48 h post-addition of Ceritinib, cells were harvested for 
ratiometric FACS analysis.
Immunofluorescence staining and confocal microscopy. The principle for p62 immunofluorescence 
follows the detailed protocol of immunofluorescence staining of LC3B described  in50. Primary antibody for p62 
(Sigma-Aldrich, Clone 2C11, WH0008878M1) was diluted 1:200 in PBS/1% BSA. Confocal microscopy was 
performed using an Olympus FluoView-1000 confocal microscope (Olympus Schweiz AG, Volketswil, Switzer-
land) with a 63 × objective. p62 dots, and carrier flux was quantified as described  in44.
Long‑lived‑protein degradation assay (LLPDA). LLPDA was performed as  in28, with slight modifica-
tions. Cells were seeded in 24-well plates at a density of 2.5 ×  104 cells/well. After cells attached, 0.1 μCi 14C-valine 
per ml was added and incubated for 24  h before the addition of Ceritinib. 18  h post-addition of the drug, 
cells were washed and incubated for 1 h in the presence of 10 mM non-radioactive L-Valine (chasing phase). 
Thereafter, cells were washed and fresh L-Valine-containing media ± autophagy inhibitors was added. After 5 h, 
precipitation of proteins in supernatant and cellular fraction was carried out using trichloracetic acid (at final 
concentration of 10%) and phosphotunctic acid (at final concentration of 1%). After incubation at 4  °C for 
30 min, samples were centrifuged at 600 rcf for 15 min to separate the TCA soluble (supernatant) from the TCA 
insoluble fraction (pellet). Radioactivity in the supernatant and the pellet fractions (after solubilisation in 0.2 M 
KOH) was determined using a scintillation counter (PerkinElmer). To determine the degradation rate of long-
lived proteins the percentage of radioactivity in the TCA-soluble fraction relative to the total radioactivity in 
both fractions was calculated. BafA- and SAR405-sensitive proteolysis was calculated by subtracting the BafA- or 
SAR405-containing sample from its corresponding BafA/SAR405 untreated condition.
Lactate de‑hydrogenase (LDH) sequestration assay. A very detailed description of the procedure 
is described  elsewhere31. Briefly, H3122 and A549 cells were seeded in a 12-well plate at a density of 2 ×  105 or 
1 ×  105 cells, respectively. After cells attached, either Ceritinib, Alectinib or Lorlatinib was administered at a final 
concentration of 1 µM for 18 h. DMSO or autophagy inhibitors were added during the last 3 h of incubation. 
Thereafter, cells were detached, resuspended in 10% sucrose and electrodisrupted using the TX ECM 630 expo-
nential decay wave electroporator (BTX) and the following settings: 800 V, 25 µF, 400 Ω. Cells were immediately 
transferred to ice-cold after blast buffer (100 mM Sodium monophosphate buffer, 2 mM EDTA, 2 mM DTT, 
1.75% Sucrose, pH 7.5). Thereafter the samples were split for determination of total and sedimentable LDH, 
respectively. Total LDH was extracted by freezing at -80 °C o/n followed by the addition of Triton-X405 (Final 
concentration 1%). Sedimentable LDH was isolated by spinning the electrodisrupted cell samples, after mix-
ing with 2 × volumes of resuspension buffer (50 mM sodium monophosphate, 1 mM DTT, 1 mM EDTA, and 
5.9% sucrose, pH 7.5) supplemented with 0.5% BSA and 0.01% Tween-20, at 18`000 rcf and 4 °C for 45 min. 
Supernatant was discarded and pellet frozen at -80 °C o/n before the addition of 1% Triton X-405. LDH activity 
was determined biochemically as the decline in absorbance at 340 nm of nicotinamide adenine dinucleotide 
(NADH) at 25 °C using a spectrophotometer (TECAN Infinite 200 PRO, Tecan Group Ltd., Männedorf, Swit-
zerland). A standard with defined NADH concentrations was used to calculate the enzyme activity (U/L) by 
applying the Beer-Lambert law.
Viability assay. For viability measurements, 2 ×  103 cells were seeded in flat-bottom 96-well culture plates. 
24 h post-seeding cells were treated with indicated concentrations of different ALK inhibitors, such as Crizo-
tinib, Ceritinib, Alectinib or Lorlatinib. 48 h post-drug-addition metabolic activity was assessed by Alamarblue 
assay (Thermo Fisher Scientific, DAL1100). Data were obtained by calculating percent reduction of Alamarblue 
according to the manufacturer’s instructions.
Trypan Blue exclusion and clonogenic assay. Cells were seeded in 6-well plates at a density of 2 ×  105 
cells/well. 24 h post-seeding, media was replaced with media containing either DMSO, 1 µM Ceritinib, 5 µM 
VSP34-IN1, 40, 80 or 120 nM Bafilomycin A1, 15 µM chloroquine, or a combination thereof. 48 h after drug 
treatment, cells were detached with trypsin–EDTA, resuspended in media, diluted 1:3 with 0.4% Trypan blue, 
and living cells were counted using a Hemocytometer. For the clonogenic assay, 5 ×  103 living cells were re-
seeded into 6-well plates and cultured for 10 days in fresh media without drugs. Thereafter, colonies were washed 
with PBS, fixed with 4% PFA for 2 min and then stained with crystal violet (0.05%) diluted in 30% ethanol for 
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1 h. After staining, colonies were washed 3 times with water, dried and counted using the GelCount colony 
counter (Oxford Optronix, Abingdon, United Kingdom).
Statistical analysis. Graph Pad Prism 7 (GraphPad Software, San Diego, USA) was used to test significance 
of our data. To compare two groups, the non-parametric Mann–Whitney U test was applied. For comparison 
of three or more groups Kruskal–Wallis followed by Dunn`s multiple comparison test was applied. Two-way-
ANOVA testing was applied to test the difference between Crizotinib and Ceritinib.
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